The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.
about
Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infectionIdentification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosaMucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.Complement system in lung disease.A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci.Analysis of the proteome of human airway epithelial secretionsHigh mortality of pneumonia in cirrhotic patients with ascites.Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice.Innate immune responses to Pseudomonas aeruginosa infection.Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungsGender-specific modulation of immune system complement gene expression in marine medaka Oryzias melastigma following dietary exposure of BDE-47.Complement in lung disease.Gene expression profiling reveals distinct features of various porcine adipose tissues.Acute lower respiratory tract infectionDecay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection.Genetic and Functional Diversity of Pseudomonas aeruginosa Lipopolysaccharide.Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection.Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.Sensing Mg2+ contributes to the resistance of Pseudomonas aeruginosa to complement-mediated opsonophagocytosis.PRELP Enhances Host Innate Immunity against the Respiratory Tract Pathogen Moraxella catarrhalis.Relative roles of complement factor 3 and mannose-binding lectin in host defense against infection.Systemic lupus erythematosus and infections: a retrospective study in Saudis.Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.Label-free SRM-based relative quantification of antibiotic resistance mechanisms in Pseudomonas aeruginosa clinical isolates.Activation of the lectin pathway of complement in experimental human keratitis with Pseudomonas aeruginosa.Hypocomplementemia in kidney transplant recipients: impact on the risk of infectious complications.Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis.A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection.Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.40 years on: have we finally got a vaccine for Pseudomonas aeruginosa?Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.Age-related variations in the in vitro bactericidal activity of human sera against Pseudomonas aeruginosa.Older Human B Cells and Antibodies
P2860
Q24684907-F90E4A1D-6CDC-49C0-8E52-8FA30906E64FQ28492950-0D30838B-DFBC-4EE9-803F-1CB8A4727FDEQ30430870-A11DCBCD-7544-48C0-9F61-5B4435F9468BQ33564290-066E4B25-7F28-4103-914A-D0F1F5FC1074Q33822579-64319C1C-9361-4B88-BA93-6F3DFB77B82BQ34305533-13D1C591-52B0-4790-AFB6-B677A8FE52F0Q34494082-64F7A2D0-EC05-4E00-BD91-FE2A540A05FDQ34564239-04CE2288-83ED-440E-A988-0BF9601B2BFAQ34580244-BD290499-A05E-4D6D-B6BB-65B06F9E7833Q35329275-B498527B-80BC-4B90-BC11-CD98CF75D332Q35566398-2718AC0F-322E-49E2-9DB6-0CA70EB9BDC2Q35738790-1E158104-1F1A-4774-A118-E884CF5281ACQ35816416-1B0277AF-3AE7-4087-BB03-FE7387F3590DQ36113743-07240601-7AC5-45C7-98A9-C5477D06B19BQ36572985-0A6362D9-13FC-477D-821B-7F570B424472Q36921885-FD612B05-E60C-45A0-805C-BA202E953DE4Q37084070-45365BF0-8863-4CAA-9D7E-9A6296C30B1EQ37106187-2A3C99EE-FBA4-47C6-88BB-2D7F8526FBA7Q37161587-369970D0-894B-4729-A1DA-B8774B01ACB9Q37701996-052B6E18-B7A7-458B-9AA0-5469EFF474A7Q37891784-52CD84E2-F449-44B8-867B-907EB6507547Q39145412-AEFF2778-882B-4F9A-842A-78A75834DA8BQ39683346-7852EA9D-12BB-4B4F-946C-E1963D7D68E6Q40094940-90B5DF17-7184-4094-B3D7-B349581AE855Q40349876-F2F10D68-5B97-4246-BD0C-B8B394D6BE40Q40381150-5694323D-11B4-4961-B032-8597EADC7396Q40440734-E929396E-C845-48D9-9717-287ED023DD39Q40508725-57CFC4F9-AE0B-48E9-AE23-34455EE38EC1Q41465136-B5F90F20-36F9-46B5-AA79-F7296A96C6E2Q41865741-0EBCF050-DC4D-47D5-A133-7E8AFB8AD7A2Q42279119-A564DA94-5290-4C0A-BB0D-BE3A1C4B3379Q42379556-C45DC3C6-DC2F-4793-B861-6E81E5F4FC29Q43121719-44C4D171-1C7C-45CD-B646-3CC8A835FC56Q44100059-732068C4-3E46-40DC-BDD6-F4089E228EAAQ45198935-C6E742C3-31BF-49C4-966F-375C38020BBCQ51532849-6743BDEB-783C-47D2-8C94-2FEF6363E647Q52448914-366E5195-1355-4D7F-BED5-13EA2DA4D0B1Q54973355-1FB3788C-533E-422A-B121-2F907D11E0B0Q58045450-1903553E-F374-41A1-8435-E9C73346814F
P2860
The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The alternative activation pat ...... n a murine model of pneumonia.
@en
The alternative activation pat ...... n a murine model of pneumonia.
@nl
type
label
The alternative activation pat ...... n a murine model of pneumonia.
@en
The alternative activation pat ...... n a murine model of pneumonia.
@nl
prefLabel
The alternative activation pat ...... n a murine model of pneumonia.
@en
The alternative activation pat ...... n a murine model of pneumonia.
@nl
P2093
P2860
P1476
The alternative activation pat ...... n a murine model of pneumonia.
@en
P2093
Rick A Wetsel
Scott M Drouin
Stacey L Mueller-Ortiz
P2860
P304
P356
10.1128/IAI.72.5.2899-2906.2004
P407
P577
2004-05-01T00:00:00Z